Literature DB >> 1400371

Carbohydrate-binding proteins in bovine kidney have consensus amino acid sequences of annexin family proteins.

K Kojima1, H K Ogawa, N Seno, K Yamamoto, T Irimura, T Osawa, I Matsumoto.   

Abstract

Ca(2+)-dependent carbohydrate-binding proteins were purified from bovine kidney extracts. Upon SDS-polyacrylamide gel electrophoresis under nonreducing conditions, the purified fraction gave doublet protein bands corresponding to 33 kDa (p33) and 41 kDa (p41). Under reducing conditions, a single protein band (p33) was observed. p33 and p41 were submitted to proteolytic digestion with endoproteinase Lys-C, the peptides produced were separated by reversed-phase high performance liquid chromatography, and their amino acid sequences were determined by an automated gas-phase protein sequenator. Most of the resulting partial amino acid sequences of these proteins were strikingly homologous to annexin IV, an annexin family protein, i.e. Ca2+/phospholipid-binding proteins, especially in the consensus sequences. In the presence of Ca2+, both proteins bound to vesicles composed of phosphatidylserine and phosphatidylethanolamine, but not phosphatidylcholine. These results indicated that p33 and p41 are members of annexin family proteins.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1400371

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  3 in total

1.  Biochemical and immunohistochemical characterization of Mimosa annexin.

Authors:  Daisuke Hoshino; Asami Hayashi; Yusuke Temmei; Nobuyuki Kanzawa; Takahide Tsuchiya
Journal:  Planta       Date:  2004-05-28       Impact factor: 4.116

Review 2.  Annexin II tetramer: structure and function.

Authors:  D M Waisman
Journal:  Mol Cell Biochem       Date:  1995 Aug-Sep       Impact factor: 3.396

Review 3.  Biological modulation by lectins and their ligands in tumor progression and metastasis.

Authors:  Susumu Nakahara; Avraham Raz
Journal:  Anticancer Agents Med Chem       Date:  2008-01       Impact factor: 2.505

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.